AssayIndex

QSC-2411-C8332

Retatrutide · 20 mg declared · Qingdao Sigma Chemical Co., Ltd. · manufactured 10 Nov 2024

CHARACTERISED
Lot code
QSC-2411-C8332
Supplier
QSC — Qingdao Sigma Chemical Co., Ltd.
Compound
Retatrutide
Compound class
Incretin analogues and co-agonists
Declared label claim
20mg
Manufacture date
10 Nov 2024
Index quarter
2024-Q4
Independent assays
6
Laboratories involved
Medutest, Janoshik, VendorInvestigate, PeptideMeter, Nordanalyt
Provenance mix
Buyer-sourced ×2 · Supplier-supplied ×4
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 6
Median purity 98.44% n=6
Spread (max − min) 0.97pp n=6
Standard deviation 0.363pp n=6
95.196.096.897.798.699.4100.3This lot (QSC-2411-C8332)This lot (QSC-2411-C8332): Q1 98.20, median 98.44, Q3 98.65, n=6n=6All RetatrutideAll Retatrutide: Q1 97.75, median 98.41, Q3 98.87, n=496outlier 95.45outlier 95.54outlier 95.67outlier 95.97n=496 Purity (% area)
Figure 1. This lot's independent purity results against the whole Retatrutide record set in the index. The vertical line is the index acceptance specification for the incretin analogues and co-agonists class, 96.5 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 6

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2024-004361QSC-2411-C8332Medutest2024-Q498.083.52Supplier-supplied1MARGINAL
AX-2024-004362QSC-2411-C8332Janoshik2024-Q499.053.40Supplier-supplied0PASS
AX-2024-004363QSC-2411-C8332VendorInvestigate2024-Q498.153.37102.4Buyer-sourced1MARGINAL
AX-2024-004364QSC-2411-C8332PeptideMeter2024-Q498.533.27Supplier-supplied0PASS
AX-2024-004365QSC-2411-C8332VendorInvestigate2024-Q498.354.0598.7Buyer-sourced1MARGINAL
AX-2024-004366QSC-2411-C8332Nordanalyt2024-Q498.693.76Supplier-supplied0PASS
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
Medutest198.0898.0825min+0.0898.00
Janoshik199.0599.0530min+0.0099.05
VendorInvestigate298.15, 98.3598.2532min-0.1198.36
PeptideMeter198.5398.5328min-0.0598.58
Nordanalyt198.6998.6935min+0.0298.67

This lot contributes 10 paired comparisons to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)98.5898.08divergence +0.14 pp vs batch median
Total impurities (% area)1.421.92
Largest single impurity (% area)0.821.03
Water (%)3.03.52
Counter-ion (%)not stated8.16
Peptide content (%w/w)not statednot determined
Endotoxin (EU/mg)not stated0.21
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
C18 diacid regioisomer6 / 60.560.08–1.03
des-Aib20 analogue6 / 60.360.14–0.64
oxidised Trp (+16 Da)6 / 60.050.05–0.11
aspartimide (−18 Da)6 / 60.040.03–0.05
retatrutide dimer5 / 60.030.02–0.06
[D-Aib2]-diastereomer3 / 60.580.52–0.60
truncated (5-39)3 / 60.340.14–0.39
Section 7

What this rollup does not establish